Company Filing History:
Years Active: 2022-2023
Title: Innovations by Daniel McGrail in Cancer Treatment
Introduction
Daniel McGrail is an accomplished inventor based in Houston, TX (US). He has made significant contributions to the field of cancer research through his innovative patents. With a focus on improving immunotherapy responses and understanding cancer metastasis, McGrail's work is paving the way for more effective treatments.
Latest Patents
Daniel McGrail holds 2 patents that address critical issues in cancer treatment. His latest patents include "Replication stress response biomarkers for immunotherapy response," which outlines methods for increasing immune therapy response and predicting the likelihood of cancer metastasis by analyzing the expression of genes associated with replication stress response. This patent emphasizes the treatment of cancers with immune checkpoint inhibitors and/or MEK inhibitors. Additionally, he has developed methods for selecting patients by analyzing gene expression related to defects in replication stress response.
Another significant patent is "Gene signatures to predict drug response in cancer." This patent focuses on identifying and treating cancers that are DNA repair-defective, particularly those sensitive to PARP inhibitors or platinum-based therapy. It provides methods for sensitizing these cancers to PARP inhibitor therapy, enhancing treatment efficacy.
Career Highlights
Daniel McGrail is affiliated with the University of Texas System, where he continues to advance his research and innovations. His work is instrumental in bridging the gap between genetic research and practical cancer therapies.
Collaborations
He collaborates with notable colleagues, including Shiaw-Yih Lin and Gordon B Mills, to further enhance the impact of his research in the field of oncology.
Conclusion
Daniel McGrail's innovative patents and research efforts are making significant strides in cancer treatment, particularly in the realm of immunotherapy and DNA repair mechanisms. His contributions are vital for the future of personalized cancer therapies.